Study Evaluating The Safety, Tolerability, And Efficacy Of Switching From Quetiapine To Ziprasidone

Schizophrenia Clinical Trial

Official title:

A Sixteen-Week, Multi-Center, Open-Label Study Evaluating The Safety, Tolerability, And Efficacy Of Switching From Quetiapine To Ziprasidone In Subjects Diagnosed With Schizophrenia Or Schizoaffective Disorder

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00406315
• Other study ID #: A1281148
• Status: Completed
• Phase: Phase 4
• Start date: November 2006
• Est. completion date: March 2009

Study information

• Verified date: March 2021
• Source: Pfizer
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The primary objective of this study is to evaluate change in weight as a result of switching from quetiapine to ziprasidone, in subjects with schizophrenia or schizoaffective disorder who have failed to achieve a satisfactory clinical response to quetiapine due to lack of efficacy or poor tolerability.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 255
• Est. completion date: March 2009
• Est. primary completion date: December 2008
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 55 Years

Eligibility

Inclusion Criteria:

• Males or females, between 18 and 55 years of age, at the time of consent.

• Subjects must have a primary diagnosis of schizophrenia, any subtype (code 295.xx), or schizoaffective disorder as defined in DSM-IV-TR (Diagnostic and Statistical Manual of Mental Disorders - Fourth Edition)

• Subjects must have normal vital signs, physical examination, ECG, and laboratory findings except for minor deviations determined and documented to be clinically insignificant by the investigator or a sub-investigator who is a medical doctor.

Exclusion Criteria:

• Subjects who are unable to provide informed consent

• Subjects who meet criteria for a DSM-IV-TR Axis I (Diagnostic and Statistical Manual of Mental Disorders - Fourth Edition) diagnosis other than schizophrenia or schizoaffective disorder, including psychoactive substance abuse or dependence within one year of study entry

• Females who are pregnant, breast feeding, or lactating at screening.

Related Conditions & MeSH terms

• Psychotic Disorders
• Schizoaffective Disorder
• Schizophrenia

Intervention

Drug:
• ziprasidone
Days 1-3: 40 mg twice a day (BID); Days 4-7: 60 mg BID; Day 8: 80 mg BID; Flexible dose between 40-80 mg BID (adjustable up to 40 mg daily/week) for the remainder of the 16-week treatment phase and continuing throughout the 16-week follow-up phase

Locations

Country	Name	City	State
Brazil	Pfizer Investigational Site	Aparecida de Goiânia	GO
Brazil	Pfizer Investigational Site	Rio de Janeiro	RJ
Brazil	Pfizer Investigational Site	São Paulo	SP
Germany	Pfizer Investigational Site	Berlin
Germany	Pfizer Investigational Site	Duesseldorf
Germany	Pfizer Investigational Site	Hamburg
Germany	Pfizer Investigational Site	Muenchen
Greece	Pfizer Investigational Site	Athens
Greece	Pfizer Investigational Site	Thessaloniki
Spain	Pfizer Investigational Site	Zamora
Turkey	Pfizer Investigational Site	Ankara
Turkey	Pfizer Investigational Site	Izmit
United States	Pfizer Investigational Site	Bothell	Washington
United States	Pfizer Investigational Site	Chicago	Illinois
United States	Pfizer Investigational Site	Costa Mesa	California
United States	Pfizer Investigational Site	Dallas	Texas
United States	Pfizer Investigational Site	Des Plaines	Illinois
United States	Pfizer Investigational Site	DeSoto	Texas
United States	Pfizer Investigational Site	Garden Grove	California
United States	Pfizer Investigational Site	Hialeah	Florida
United States	Pfizer Investigational Site	Kirkland	Washington
United States	Pfizer Investigational Site	Las Vegas	Nevada
United States	Pfizer Investigational Site	Memphis	Tennessee
United States	Pfizer Investigational Site	Memphis	Tennessee
United States	Pfizer Investigational Site	Miami	Florida
United States	Pfizer Investigational Site	Miami	Florida
United States	Pfizer Investigational Site	Nashua	New Hampshire
United States	Pfizer Investigational Site	National City	California
United States	Pfizer Investigational Site	Oakbrook Terrace	Illinois
United States	Pfizer Investigational Site	Olean	New York
United States	Pfizer Investigational Site	Olive Branch	Mississippi
United States	Pfizer Investigational Site	Orange	California
United States	Pfizer Investigational Site	Phoenix	Arizona
United States	Pfizer Investigational Site	Saint Louis	Missouri
United States	Pfizer Investigational Site	San Diego	California
United States	Pfizer Investigational Site	Schaumburg	Illinois
United States	Pfizer Investigational Site	Staten Island	New York
United States	Pfizer Investigational Site	Temecula	California
United States	Pfizer Investigational Site	Topeka	Kansas
United States	Pfizer Investigational Site	Torrance	California

Sponsors (1)

Lead Sponsor	Collaborator
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

Countries where clinical trial is conducted

United States,  Brazil,  Germany,  Greece,  Spain,  Turkey, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change From Baseline in Weight at Week 16	Weight value: Change = value at Week 16 or Week 16 Last Observation Carried Forward (LOCF) minus value at Baseline.	Baseline, Week 16, Week 16 LOCF
Secondary	Change From Baseline in Fasting Lipid Profile (Total Cholesterol) at Week 16	Total cholesterol value: Change = value at Week 16 minus value at Baseline.	Baseline, Week 16
Secondary	Change From Baseline in High-Density Lipoprotein (HDL), Low-Density Lipoprotein (LDL), and Triglycerides at Week 16	HDL, LDL, and triglyceride value: Change = value at Week 16 minus value at Baseline.	Baseline, Week 16
Secondary	Change From Baseline in Glycosylated Hemoglobin A1c (HbA1c) at Week 16	HbAlc value: Change = value at Week 16 minus value at Baseline.	Baseline, Week 16
Secondary	Change From Baseline in Fasting Glucose at Week 16	Fasting glucose value: Change = value at Week 16 minus value at Baseline.	Baseline, Week 16
Secondary	Change From Baseline in Fasting Insulin at Week 16	Fasting insulin value: Change = value at Week 16 minus value at Baseline.	Baseline, Week 16
Secondary	Change From Baseline in Waist and Hip Circumference at Week 16	Waist and hip circumference value: Change = value at Week 16 minus value at Baseline.	Baseline, Week 16
Secondary	Change From Baseline in Abnormal Involuntary Movement Scale (AIMS) Total Score, Global Severity Score, and Global Incapacitation Score at Week 16	AIMS: a 12-item clinician administered instrument assessing observed abnormal movements in different parts of body. Ten items scored on a 5-point scale (0 = none/normal, 4 = severe) evaluate abnormal movements in three main anatomic areas (orofacial area, extremities, and trunk). Two items are yes/no questions regarding dentures. Total scores range from 0 to 42. Item 8 indicates severity, item 9 indicates Incapacitation. AIMS total, global severity, or global incapacitation score: Change = score at Week 16 minus score at Baseline.	Baseline, Week 16
Secondary	Change From Baseline in Positive and Negative Symptoms of Schizophrenia (PANSS) Total Score, and Positive and Negative Subscale Scores at Week 16	PANSS measures severity of psychopathology in subjects with schizophrenia, schizoaffective disorder and other psychotic disorders. It includes 3 scales and a total of 30 items: 7 items comprise the positive scale, 7 comprise the negative scale, and 16 items measure general psychopathology. Each item is rated on a scale from 1 (symptom not present) to 7 (symptoms extremely severe). The sum of the 30 items is defined as the PANSS total score and ranges from 30 to 210. PANSS total score and positive and negative scores: Change = score at Week 16 or Week 16 LOCF minus score at Baseline.	Baseline, Week 16, Week 16 LOCF
Secondary	Change From Baseline in Clinical Global Impression Severity Scale (CGI-S) at Week 16	The CGI-S is a single item, clinician-rated scale that assesses the global severity of the subject's overall illness. The CGI-S ratings range from 1 (normal, not at all ill) to 7 (among the most severely ill subjects). CGI-S score: Change: score at Week 16 or Week 16 LOCF minus score at Baseline.	Baseline, Week 16, Week 16 LOCF
Secondary	Observed Cases of Clinical Global Impression Improvement Scale (CGI-I) Scores at Week 16	The CGI-I is a 7-point, single-item, clinician-rated scale that assesses global improvement in the subject's clinical state in response to study treatment, and as compared to their status at pre-treatment baseline. Possible CGI-I scores range from 1 (very much improved) to 4 (no change) to 7 (very much worse).	Week 16, Week 16 LOCF
Secondary	Change From Baseline in Calgary Depression Scale for Schizophrenia (CDSS) Total Score at Week 16	The CDSS is a 9-item, clinician-rated scale validated for rating the severity of depressive symptoms in subjects diagnosed with schizophrenia, and independent of confounding negative and extrapyramidal symptoms. The CDSS rates the severity of depressive symptoms on a 4-point scale ranging from 0 (absent) to 3 (severe). The CDSS depression total score is obtained by adding each of the item scores. Total possible score ranges from 0 to 27. CDSS possible total score: Change: score at Week 16 or Week 16 LOCF minus score at Baseline.	Baseline, Week 16, Week 16 LOCF
Secondary	Change From Baseline in Schizophrenia Cognition Rating Scale (SCoRS) Total Score and Global Rating at Week 16	The SCoRS is a 20-question rating scale completed via interviews with the subject and an informant, focusing on cognitive impairment and its impact on daily functioning. Each question was completed using a 4-point scale (ranging from 1=none to 4=severe). Total possible score ranged from 20 to 80. At the end of the 20 questions, the interviewer completed a Global Scale of 1-10, rating subject's overall difficulty. Higher scores on both indicated greater cognitive impairment. SCoRS total score and global rating: Change: score at Week 16 or Week 16 LOCF minus score at Baseline.	Baseline, Week 16, Week 16 LOCF
Secondary	Change From Baseline in Global Assessment of Function Scale (GAF) Score at Week 16	GAF Scale measures the severity of illness-related impairment in psychological, social, and occupational functioning using a 100-point scale. Total possible score ranges from 0 (not enough information available to provide GAF) to 100 (Superior functioning in a wide range of activities, life's problems never seem to get out of hand, is sought out by others because of his or her many qualities. No symptoms). The assessment was done by a trained assessor. GAF scale score: Change: score at Week 16 or Week 16 LOCF minus score at Baseline.	Baseline, Week 16, Week 16 LOCF
Secondary	Change From Baseline in Treatment Satisfaction Questionnaire for Medication (TQSM) Effectiveness, Side Effect, Convenience, and Global Satisfaction Subscales at Week 16	The TSQM is a 13-item subject-rated scale that evaluates the effectiveness, side effects and convenience of the medication over the past 2-3 weeks. Likert scale: 1=Extremely Dissatisfied, 2=Very Dissatisfied, 3=Somewhat Dissatisfied, 4=Neither Satisfied Nor Dissatisfied, 5=Somewhat Satisfied, 6=Very Satisfied, 7=Extremely Satisfied. Worst value is 0 and best value is 100. TSQM Effectivenss, Side Effect, Convenience, and Global Satisfaction scores: Change: score at Week 16 or Week 16 LOCF minus score at Baseline.	Baseline, Week 16, Week 16 LOCF

External Links

•   To obtain contact information for a study center near you, click here.